PBS Calendars

Page last updated: 7 August 2017

PBS related activities surrounding the PBAC meeting cycles

If you are considering applying to have a drug listed on the PBS, it is recommended that you contact the Office of Health Technology Assessment (OHTA) to discuss the listing steps. If you are unsure of the most appropriate person to contact, the Industry Liaison Officer will be able to assist.

All contact details are available from the PBS contacts page.

PBAC Cycle Timeframe for 2017 - 2018

Week

Activity

PBAC Cycle
2017/2

Meeting Date: 5-7
July

PBAC Cycle
2017/3

Meeting Date:
1-3
November

PBAC Cycle
2018/1

Meeting Date:
7-9
March

PBAC Cycle
2018/2

Meeting Date:
4-6
July

PBAC Cycle
2018/3

Meeting Date:
31 Oct - 2 Nov

0

Deadline for major submissions (Wednesday)

8 March 2017

5 July 2017

1 Nov 2017

7 Mar 2018

4 July 2018

1

 

 

 

 

 

2

 

 

 

 

 

3

 

 

 

 

 

4

 

 

 

 

 

5

Submissions to discussants (Wednesday)


Pre submission meetings with companies
(future submissions only)

12 April 2017


10 Apr – 5 May 2017
(14,17,25 Apr PH)

9 Aug 2017


7 Aug – 1 Sept 2017

6 Dec 2017


4 Dec 17 – 5 Jan 2018
(25,26 Dec,1 Jan PH)

13 April 2018


9 Apr – 4 May 2018

8 Aug 2018


6 Aug – 31 Aug 2018

6

Deadline for minor submissions (including Secretariat listings) (Friday)

 

21 April 2017

18 Aug 2017

15 Dec 2017

20 Apr 2018

17 Aug 2018

7

Publication of PBAC agenda on PBS website (Wednesday)

Consumer comments open

26 April 2017
(25 Apr PH)

23 Aug 2017

20 Dec 2017

27 Apr 2018

22 Aug 2018

8

 

 

 

 

 

9

 

 

 

 

 

10

Major submission commentaries to “Responsible Persons” (Wednesday)

 

17 May 2017

13 Sept 2017

17 Jan 2018

16 May 2018

12 Sept 2018

11

“Responsible Persons” send Pre-Subcommittee Responses to PBAC Secretariat (by midday Wednesday)


Pre submission meetings with companies (future submissions only)

 

24 May 2017




22-26 May 2017

20 Sept 2017




18-22 Sept 2017

24 Jan 2018




22-26 Jan 2018

23 May 2018




21-25 May 2018

19 Sept 2018




17-21 Sept 2018

12

DUSC meeting (Thursday-Friday)

 

1-2 June 2017

28-29 Sept 2017

1-2 Feb 2018

31 May-1 June 2018

27-28 Sept 2018

13

ESC meeting (Monday-Tuesday)


Closing date for online consumer comments

 

5-6  June 2017


7 June 2017

3-4 Oct 2017
(2  Oct PH)

4 Oct 2017

5-6 Feb  2018


7 Feb 2018

4-5 June 2018


6 June 2018

2-3 Oct 2018 (1 Oct PH)

3 Oct 2018

14

ATAGI meeting (Thursday – Friday)

15-16 June 2017

12-13 Oct 2017

15-16 Feb 2018

14-15 June 2018

11-12 Oct 2018

15

Minor submission overviews, ESC (major submissions only), DUSC (selected major submissions only), & ATAGI (vaccine submissions only) advice & summary of consumer comments to “Responsible Persons” (Wednesday)

 

21 June 2017

18 Oct 2017

21 Feb 2018

20 June 2018

17 Oct 2018

16

“Responsible Persons” send Pre-PBAC Responses to PBAC Secretariat (by midday Wednesday)


Pre submission meetings with companies not relating to imminent submissions(future submissions only)

 

28 June 2017




26-30 June 2017

25 Oct 2017




23-27 Oct 2017

28 Feb 2018




26 Feb – 2 Mar 2018

 

27 June 2018




25-29 June 2018

24 Oct 2018




24-26 Oct 2018

17

PBAC meeting Wednesday-Friday


(Close for next cycle major submissions on Wednesday)

5-7 July 2017


5 July 2017

1-3 Nov 2017


1 Nov 2017

7-9 Mar 2018
 

7 Mar 2018

4-6 Jul 2018


4 Jul 2018

31 Oct-2 Nov 2018

31 Oct 2018

18

POST PBAC PROCEDURES:

 

 

 

 

19

 

 

 

 

 

20

Ratified Minutes (positive recommendations) to “Responsible Persons” (Friday)

28 July 2017

24 Nov 2017

29 Mar 2018
(30 Mar PH)

27 Jul 2018

23 Nov 2018

21

 

 

 

 

 

22

Ratified Minutes (all other recommendations) to “Responsible Persons” (Friday)

 

11 Aug 2017

8 Dec 2017

13 Apr 2018

10 August 2018

7 Dec 2018

23

Posting of recommendations on website following sponsor’s comments*
(Friday)

18 Aug 2017

15 Dec 2017

20 Apr 2018

17 August 2018

14 Dec 2018

24

Deadline for Independent Review requests for reconsideration at the meeting following the next meeting (Friday)

25 Aug 2017

22 Dec 2017

27 Apr 2018

24 August 2018

21 Dec 2018

25

 

 

 

 

 

26

 

 

 

 

 

27

Draft PSDs  to “Responsible Persons”(Friday)

15 Sept 2017

19 Jan 2018

18 May 2018

14 Sept 2018

18 Jan 2019

28

 

 

 

 

 

29

 

 

 

 

 

30

 

 

 

 

 

31

 

 

 

 

 

32

Finalisation of PSDs (Friday)

 

20 Oct 2017

23 Feb 2018

22 June 2018

19 Oct 2018

22 Feb 2019

33

PSDs published on web site (positives & subsequent rejections)
(Friday)

27 Oct 2017

2 Mar 2018

29 June 2018

26 Oct 2018

1 March 2019

0

 

 

 

 

 

1

PSDs published on web site (1st time rejections & deferrals)
(Friday)

10 Nov 2017

16 Mar 2018

13 July 2018

9 Nov 2018

 

15 March 2019

PBAC = Pharmaceutical Benefits Advisory Committee
“responsible persons” = legal wording requirement for terminology – previously known as sponsors
DUSC = Drug Utilisation Sub Committee    
ESC = Economic Sub Committee
ATAGI = Australian Technical Advisory Group on Immunisation
PSDs = Public Summary Documents
TBC = To be Confirmed
    
*  These dates may vary based on the number of submissions received    

Accessibility

The documents on this page may not be accessible. If you need help please contact HTA compliance (secretariat.compliance@health.gov.au).

Suitable Dates for Sponsors to meet with the Office of Health Technology Assessment (OHTA)

It is quite routine for sponsors to meet with relevant officers in the OHTA prior to submitting to the PBAC, however, the available opportunities for these meetings is limited by busy periods within the PBAC meeting cycle when key personnel have other priorities.

The weeks in the cycles assigned for OHTA-Sponsor meetings can be found in the PBAC Cycle Timeframe Calendar.

Please complete and return the meeting request form (Word 23 KB) to HTA compliance (secretariat.compliance@health.gov.au).

Once your request form has been received and reviewed by the OHTA a Departmental officer will be in touch to arrange a meeting time.

If the item to be discussed is a co-dependent technology sponsors must first contact the Health Technology Assessment (HTA) team (hta@health.gov.au) to arrange a joint meeting.

Health technologies are co-dependent if their use needs to be combined (either sequentially or simultaneously) to achieve or enhance the intended clinical effect of either technology.  For example, a drug/test combination where a new medicine seeking listing on the PBS may have a related pathology test that helps to determine the population group for that medicine.

Further information about the HTA processes can be found on the Department of Health website.